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Abstract
Background and Aims: There is an increasing incidence of inflammatory bowel disease [IBD]. 
Autoimmune responses are involved in the pathophysiology of IBD, but their underlying pathways 
and target antigens have not yet been fully elucidated.
Methods: Autoantigenic targets in IBD were identified after separation of whole cell proteins 
isolated from neutrophils using two-dimensional electrophoresis and matrix assisted laser 
desorption ionization – time of flight mass spectrometry-based protein identification of the spots 
that displayed Western blotting signals with anti-neutrophil cytoplasmic antibody-positive sera. 
The prevalence of IgG, IgA and secretory IgA [sIgA] to chitinase 3-like protein 1 [CHI3L1] was 
analysed by enzyme-linked immunosorbent assays using recombinant CHI3L1 in 110 patients with 
Crohn’s disease [CD], 95 with ulcerative colitis [UC], 126 with coeliac disease [CeD] and 86 healthy 
controls [HCs].
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.  
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Results: The 18-glycosylhydrolase family member CHI3L1 was identified as a neutrophil 
autoantigenic target. CD patients displayed significantly higher levels of IgG to CHI3L1 than 
patients with UC and CeD (p < 0.0001, respectively). IgA and sIgA to CHI3L1 was significantly 
higher in CD than in UC, CeD and HCs [p  <  0.0001, respectively]. IgA and sIgA to CHI3L1 
demonstrated the highest prevalence in CD [25.5%, 28/110; and 41.8%%, 46/110] compared to 
HCs [2.3%, 2/86; and 4.7%%, 4/86; p = 0.0015 and p < 0.0001] and are associated with a more 
complicated progression of CD.
Conclusion: CHI3L1 is a novel neutrophil autoantigenic target in CD. IgA and sIgA to CHI3L1 may 
serve as novel markers for CD and may facilitate the serological diagnosis of IBD.
Key Words: Inflammatory bowel disease; chitinase-3 like protein 1; autoantibody; Crohn’s disease; enzyme-linked immunosorbent 
assay
1. Introduction
Inflammatory bowel diseases [IBDs] are most prevalent in devel-
oped countries, affecting around one in 250 individuals. Their 
incidence in developing countries acquiring a Western lifestyle is 
rising.1 However, the aetiology of IBD is not yet fully understood.2 
Based on clinical and pathological features, IBD can be divided 
into two main clinical entities: Crohn’s disease [CD] and ulcerative 
colitis [UC]. The latter is locally limited to the colon and rectum 
and characterized by a diffuse mucosal inflammation. In contrast, 
CD can affect the whole gastrointestinal tract from the mouth to 
the rectum with transmural inflammation.3,4 Environmental fac-
tors, genetic predisposition, dysfunction of the intestinal mucosal 
barrier and dysregulation of immune responses are involved in the 
manifestation of IBD.5,6
Autoimmune responses are considered as a part of IBD 
inflammation. Disease-specific autoantibodies [autoAbs] against 
neutrophils,7,8 intestinal goblet cells9,10 and exocrine pancreas11 
have been reported. Of note, the pancreatic major zymogen mem-
brane glycoprotein 2 [GP2] was identified as the first autoanti-
genic target located at the site of CD inflammation11 and exerting 
modulation of innate and acquired immune responses in CD.12,13 
Anti-neutrophil cytoplasmic antibodies [ANCA] and especially 
perinuclear ANCA [pANCA] have a prevalence of up to 70% in 
UC and up to 10% in CD patients.14 Of interest, elevated levels of 
autoAbs to neutrophil proteinase 3 [PR3] detected by highly sen-
sitive immunoassays have been reported in UC recently.15,16 Thus, 
loss of tolerance to neutrophil antigens may play a pathophysi-
ological role in IBD.
Neutrophils contribute to the first line of host defense, but are 
also involved in IBD inflammatory processes characterized by a 
concomitant dysregulated microbiota.17 Phagocytosis and produc-
tion of reactive oxygen species by neutrophils are defective in IBD 
patients.18,19 This can lead to bacterial accumulation and continuous 
recruitment of neutrophils to the inflamed mucosa. Thus, neutro-
phils may play an important role in the onset or perpetuation of IBD 
inflammation.
The aim of this study was to identify novel neutrophil autoan-
tigenic targets possibly involved in sensing the intestinal micro-
biota as well as IBD inflammation. For the first time, we provide 
evidence that chitinase-3-like protein 1 [CHI3L1] overexpressed in 
enterocytes during inflammation of the large bowel and to support 
the uptake of pathogenic intestinal bacteria is a novel neutrophil 
autoantigenic target in CD.
2. Methods
2.1. Patient samples
In total, 331 patient samples were collected at the Pediatric Clinic 
[Technical University of Dresden, Germany]. Samples included 110 
sera of patients with CD, 95 with UC and 126 with coeliac disease 
[CeD] [Table 1]. The diagnosis of IBD was established according 
to the Porto criteria of the IBD Working Group of the European 
Society for Pediatric Gastroenterology Hepatology and Nutrition 
and was based on clinical, radiological, endoscopic and histological 
evaluation. For serological analysis, serum samples taken around 
the date of diagnosis were used and retrospectively investigated. For 
the description of disease localization, disease behaviour and age of 
manifestation of our paediatric IBD cohort, we used the Montreal 
classification of IBD with its paediatric modification, the Paris clas-
sification [Table 2].
Eighty-six healthy controls [HCs] were obtained from in.vent 
Diagnostica [Hennigsdorf, Germany]. Additionally, eight serum 
samples with high ANCA titres [>1:320] from patients with IBD 
were used for protein identification.
Table 1. Demographic data of the study population
 n Male/female [%] Median age, years [Q1; Q3] Median CRP, mg/l [Q1; Q3]
CD 110 68/42 [61.5/38.5] 13 [10; 15] 22.7 [8.2; 50.8]
UC 95 43/52 [/45.3/54.7] 14 [10; 15] 3.7 [1; 11]
CeD 126 46/80 [36.5/63.5] 8 [3; 14] N/A
HC 86 52/34 [60.6/39.4] 28 [21; 41] N/A
CRP, C-reactive protein; Q, quartile; CD, Crohn’s disease; UC, ulcerative colitis; CeD, coeliac disease; HC, healthy controls.
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2.2. Isolation of human neutrophils
Neutrophils were isolated as described previously.20 In brief, anti-
coagulated blood [K2-EDTA] was layered over an equal amount of 
PolymorphPrep [Axis Shield] and centrifuged at 480 g for 30 min. 
The leukocyte band was harvested, resuspended in phosphate buff-
ered saline with 0.2% bovine serum albumin [PBS-BSA] and cen-
trifuged at 480 g for 10 min. Contaminating red blood cells were 
removed by adding lysing solution, 2 min of incubation at room 
temperature and centrifugation as before. Cells were washed twice 
with PBS-BSA and finally resuspended in PBS-BSA.
2.3. Two-dimensional electrophoresis and 
immunoblotting
Neutrophil proteins were extracted by sonication [pulse: 1 s, brake: 
20 s, amplitude: 45%, on ice, Bandelin Sonoplus; Bandelin Electronic] 
in lysis buffer [50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% NP-40, 
0.5 mM EDTA, Protease Inhibitor Cocktail] with subsequent centri-
fugation for pelleting cell debris as described elsewhere.21 Following 
acetone precipitation, neutrophil proteins were separated by two-
dimensional gel electrophoresis [2DE] using isoelectric focusing 
[IEF] dry strips [Immobiline DryStrips pH 3–10], Ettan IPGphor 3 
IEF System [GE Healthcare] and followed by vertical electrophoresis 
with the PerfectBlue Gel System Mini L [VWR].22 Semi-dry blotting 
to PVDF membranes [Roth] was performed with samples for im-
munoblotting, followed by blocking with 5% skimmed milk powder 
in PBS and 0.1% Tween-20 [PBST]. Membranes were incubated 
with serum samples diluted 1:100 in 2% skimmed milk powder in 
PBST for 1 h, washed with PBST and subsequently incubated with 
horseradish peroxidase-conjugated anti-human immunoglobulin 
G [IgG]. Reactive spots were analysed with a UV-transilluminator 
[BioDocAnalyze, Biometra] by enhanced chemiluminescence [ECL].
For spot excision and protein identification, separate 2DE gels 
were performed and visualized by staining with Coomassie Brilliant 
Blue R250 [Roth].23
2.4. Protein identification using MALDI TOF-MS
Protein spots that displayed Western blot signals were excised from 
Coomassie-stained 2D gels and subjected to in-gel tryptic digestion 
as described elsewhere.21 Proteins were identified using matrix-
assisted laser desorption ionization time of flight mass spectrometry 
[MALDI TOF MS/MS; Ultraflex III TOF/TOF, Bruker Daltonics] as 
described.21
2.5. Expression of recombinant CHI3L1
For the recombinant expression of human CHI3L1, the Gateway 
Technology [Invitrogen] was used. In brief, primers flanking the full-
length cDNA of CHI3L1 [accession number NM_001276.2], add-
ing a C-terminal polyhistidine-tag and Gateway recombination sites 
were designed to amplify CHI3L1 cDNA from the human intestinal 
cell line CaCo-2. The amplification product was further processed 
according to the manufacturer’s guidelines. The recombinant vector 
pDEST8_CHI3L1 was used to transform Escherichia coli DH10Bac 
generating recombinant bacmid DNA, which was used to transfect 
cultured Sf9 [Spodoptera frugiperda] insect cells to produce recom-
binant baculovirus expressing CHI3L1. The protein was harvested 
from the supernatant and purified by Ni-chelate chromatography 
and dialysed against 20  mM sodium phosphate buffer [pH 7.5] 
following sodium dodecyl sulfate polyacrylamide gel electropho-
resis [SDS-PAGE] and Coomassie staining to confirm the purity of 
CHI3L1.
2.6. Enzyme-linked immunosorbent assay
The enzyme-linked immunosorbent assay [ELISA] technique was 
used for detection of CHI3L1 autoAbs in serum samples by using 
recombinant human CHI3L1 as solid-phase antigen. Briefly, 2 µg/
ml CHI3L1, diluted in bicarbonate buffer [pH 9.5], was coated on 
microtitre plates [Greiner Bio-one] overnight at 4°C. After blocking 
with 2% bovine serum albumin at room temperature for 1 h, the 
plates were incubated with serum samples [diluted 1:100 in sample 
buffer] for 1  h at room temperature. After washing, horseradish 
Table 2. Characteristics of inflammatory bowel disease patients according to Paris classification
 CD [n = 110]  UC [n = 95]
Age at diagnosis, n [%]
Below 10 years [A1a] 24 [21.8]  17 [17.9]
10–17 years [A1b] 84 [76.4]  69 [72.6]
17–40 years [A2] 1 [0.9]  9 [9.5]
Above 40 years [A3] 0  0
Location, n [%] Extent  
Ileal [L1] 17 [15.5] Proctitis [E1] 5 [5.3]
Colonic [L2] 13 [11.8] Left-sided UC [E2] 13 [13.7]
Ileocolonic [L3] 80 [72.7] Extensive [E3] 7 [7.4]
Upper disease, modifier [L4] N/A Pancolitis [E4] 70 [73.7]
Behaviour, n [%]   
Non-stricturing, non-penetrating [B1] 59 [53.6]   
Stricturing [B2] 36 [32.7]   
Penetrating [B3] 2 [1.8]   
Stricturing and penetrating [B2+B3] 13 [11.8]   
BMI – median, kg/m2 [Q1/Q3] 16.5[14.7/18.2]  N/A
Location and behaviour of CD is defined as: L1, ileal involvement; L2, colonic involvement; L3, ileocolonic involvement; B1, non-stricturing and non-penetrat-
ing manifestation; B2, structuring manifestation [stenosis]; B3, penetrating manifestation; B2+B3, stricturing and penetrating manifestation. Extent of UC is defined 
as: E1, ulcerative proctitis; E2, left-sided UC [distal to splenic flexure]; E3, extensive [hepatic flexure distally]; E4, pancolitis [proximal to hepatic flexure]. BMI, 
body mass index; Q, quartile; N/A, not available.
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peroxidase-conjugated anti-human IgA, IgG [Dianova] or anti-
human IgA secretory component [antibodies-online] were added. 
Plates were developed with ready-to-use TMB substrate [Seramun 
Diagnostik] and stopped with 0.25 M sulphuric acid after 10 min. 
The optical density [OD] was read at 450 nm/620 nm in a micro-
plate reader [Sunrise, Tecan Trading].
2.7. Statistical analysis
Statistical analyses were performed using GraphPad Prism ver-
sion 6.00 for Windows [GraphPad Software]. Data were tested for 
normality by a Kolmogorov–Smirnov test. Statistically significant 
differences were determined by two-tailed, non-parametric Mann–
Whitney U test for independent samples. Levels of significance of 
differences in prevalence were calculated in contingency tables by 
a two-tailed Fisher’s exact test. The median and 95% confidence 
interval [CI] were used to express the measured data. On the basis 
of a significance level of 0.05, the Bonferroni correction was used 
to account for multiple comparison problems. MedCalc software 
version 12.4.0 [MedCalc] was used to perform receiver operating 
characteristic [ROC] curve analysis.
3. Results
3.1. Identification of CHI3L1 as an autoantigenic 
target in neutrophils
Neutrophils isolated from the blood of three healthy donors were 
lysed and neutrophil proteins separated by 2DE [Figure 1A]. 
Separated 2DE gels were semi-dry blotted onto PVDF membranes 
and probed with ANCA-positive sera of patients diagnosed with 
IBD. Reactive spots were detected by ECL after incubation with 
peroxidase-conjugated human IgG [Figure 1B]. Among other known 
neutrophil antigenic targets such as PR3 or lactoferrin a reactive 
spot with an apparent molecular weight of 40 kDa and an isoelec-
tric point of pH 8.5 was detected in four of eight high-titre ANCA 
sera. There was no reactivity when tested with control sera from 
healthy donors [Figure 1C]. Subsequent MALDI-TOF MS and data-
base searches identified the reactive spot as CHI3L1 protein with a 
MOWSE [molecular weight search] score of 110 and sequence cov-
erage of 37%.
3.2. Immunoglobulin reactivity to CHI3L1 of IBD 
sera by ELISA
Since CHI3L1 is expressed in colonic epithelial cells, the CaCo-2 
cell line was used to amplify CHI3L1 cDNA for subsequent gen-
eration of recombinant baculovirus and expression of CHI3L1 in 
Sf9 cells. To reveal possible variations due to differences in post-
translational glycosylation, the reactivity of the protein produced 
recombinantly in insect cells was compared with commercially 
available protein produced in human cells [Sino Biological, Cat. 
No. 11227-H08H] by means of ELISA. However, there was no dif-
ference of CHI3L1 reactivity to healthy controls or disease groups 
[Supplementary Figure 1], suggesting a comparable glycoslyla-
tion and structural similarity among epitopes. Purified recombi-
nant CHI3L1 was used as solid-phase antigen for the detection 
of CHI3L1 autoAbs in patient and control samples. The level of 
CHI3L1 autoAbs was read as the ratio of ODsample/ODcutoff [ODcutoff, 
3 sigma of HC times OD of internal calibration serum] for stand-
ardization. Sera from patients with CD showed higher IgG reac-
tivity to CHI3L1 [median ratio, 0.532; 95% CI, 0.510–0.610] 
than sera from HC [median ratio, 0.468; 95% CI, 0.396–0.540; 
p  =  0.0196; Figure 2A]. Compared to patients with either UC 
[median ratio, 0.412; 95% CI, 0.382–0.451] or CeD [median 
ratio, 0.287; 95% CI, 0.260–0.304], IgG reactivity to CHI3L1 was 
significantly higher [both p < 0.0001]. In contrast, IgG reactivity 
to CHI3L1 of UC and CeD patient sera was lower than in HC 
[p = 0.0155 and p < 0.0001, respectively].
The same relationship was found when IgA reactivity to 
CHI3L1 was analysed in different patient cohorts. There was 
a significantly higher IgA reactivity in CD [median ratio, 0.658; 
95% CI, 0.566–0.755] than in HC [median ratio, 0.384; 95% 
CI, 0.326–0.444; p < 0.0001], UC [median ratio, 0.360; 95% CI, 
0.307–0.408; p < 0.0001] and CeD patients [median ratio, 0.294; 
95% CI, 0.249–0.359; p < 0.0001, Figure 2B]. In addition, secre-
tory IgA [sIgA] reactivity was the highest in CD patients [median 
ratio, 0.798; 95% CI, 0.689–1.027] and differed significantly from 
UC [median ratio, 0.516; 95% CI, 0.384–0.641; p < 0.0001], CeD 
[median ratio, 0.424; 95% CI, 0.377–0.490; p < 0.0001] and HC 
sera [median ratio, 0.437; 95% CI, 0.350–0.492; p  <  0.0001; 
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Figure 1. Two-dimensional electrophoresis of neutrophil lysates. In the first dimension, proteins were separated by isoelectric focusing followed by SDS-PAGE 
in the second dimension and subsequently stained with Coomassie blue [A]. The rectangle marks the spot with an apparent isoelectric point of pH 8.5 and 
molecular weight of 40 kDa identified as chitinase-3-like protein 1 protein by MALDI-TOF mass spectrometry. Immunoblotting of neutrophil proteins separated 
by two-dimensional electrophoresis and incubated with patient sera [B] or sera from healthy controls [C] followed by enhanced chemiluminescence detection 
after incubation with peroxidase-conjugated IgG. Arrow marks the reactive spot that was identified as CHI3L1. Circles mark the known neutrophil antigenic 
targets proteinase 3 [PR3] and lactoferrin [LTF].
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3.3. Prevalence of positive CHI3L1 autoAbs in IBD
After having determined cut-off values, we found 9.1% [10/110] of 
CD, none of UC, 2.4% [3/126] of CeD and 2.3% [2/86] of HC sera 
positive for IgG to CHI3L1, and there was no significant difference 
when comparing different disease groups and the HC group Table 3 
Supplementary Table 1]. There was a trend of higher prevalence in 
CD patients, which was significant when compared to UC patients 
[p = 0.002]. We found a significantly higher prevalence of positive 
IgA and sIgA to CHI3L1 in patients with CD when compared to HC 
[28/110 vs 2/86, p < 0.0001; 46/110 vs 4/86, p < 0.0001]. In con-
trast, there was no significantly higher prevalence of these CHI3L1-
reactive Ig classes in CeD patients and only a barely significantly 
elevated prevalence of positive sIgA to CHI1L3 in UC patients 
[17/95 vs 4/86; p = 0.0055]. When comparing disease groups, we 
found a higher prevalence of positive IgA and sIgA to CHI3L1 in 
CD than in UC [both p < 0.0001] or CeD patients [p = 0.0034 and 
p = 0.0002, respectively] [Supplementary Table 1].
3.4. Diagnostic relevance of CHI3L1 autoAbs
ROC curve analysis was used to determine general cut-off values and 
to evaluate the diagnostic potential of CHI3L1 autoAbs, applying 
different clinical scenarios. For the identification of CD among 
healthy subjects, we performed ROC analysis with CD [n = 110] vs 
healthy blood donors [negative criterion; HC; n  = 86] Figure 3A. 
The assay was performed with disparate outcomes when using anti-
human IgG, IgA or sIgA, with area under the curve [AUC] values 
between 0.597 and 0.781, and with better outcomes with the sIgA 
CHI3L1 autoAbs [Table 4].
AUC values ranging from 0.694 to 0.712 were achieved for dif-
ferentiation of CD vs UC [negative criterion; n = 95] with best diag-
nostic utility for IgA [AUC 0.712] Figure 3B. However, the cut-off 
values at 95% specificity were higher than calculated for the identi-
fication of CD among healthy individuals.
In addition, we performed ROC analysis for CD vs disease 
and healthy controls [negative criterion; UC = 95, CeD = 126 and 
HC = 86] with AUC values ranging from 0.729 to 0.748. For this 
scenario, the assay performs best with IgG CHI3L1 autoAbs [AUC 
0.748]. Similar or higher cut-off values at 95% specificity than for 
the differentiation of CD and UC were calculated [Supplementary 
Table 2, Supplementary Figure 2].
Furthermore, Ig reactivities were compared with other clinical 
parameters such as C-reactive protein [CRP] and anti-Saccharomy-
ces cerevisiae antibodies [ASCA] [Table 5]. There was no correlation 
of Ig reactivity to CHI3L1 with CRP or ASCAs in CD, UC and CeD 
patients.
3.5. Association of CHI3L1 autoAbs with the 
localization of inflammation in CD patients
When comparing patients with ileal involvement [L1, n = 17] and 
colonic involvement [L2, n = 13], there was no significant difference 
but a trend towards higher reactivity to CHI3L1 of all Ig subclasses 

































































Figure 2. Median ratio of ODsample/ODcutoff of anti-CHI3L1 IgG, IgA and sIgA. [A] IgG reactivity to CHI3L1 was significantly higher in CD patients than in UC 
[p < 0.0001], CeD [p < 0.0001] and HC group sera [p < 0.05]. UC and CeD group showed significantly lower IgG reactivity to CHI3L1 compared to HCs [p < 0.05; 
p < 0.0001]. There is a significantly higher IgA [B] and secretory component [C] reactivity to CHI3L1 in CD patients [p < 0.0001] compared to UC, CeD and control 















































Figure 3. Receiver operating characteristic curve analysis of CHI3L1 autoAbs. [A] CD vs healthy controls. Disease group [positive criterion]: 110 patients with CD, 
control group [negative criterion]: 86 blood donors. [B] CD vs UC. Disease group [positive criterion]: 110 patients with CD, control group [negative criterion]: 95 
patients with UC. CD, Crohn’s disease; UC, ulcerative colitis.
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p = 0.2415]. Independent of Ig type, there was no significant differ-
ence in Ig reactivity when comparing L1 and patients with ileoco-
lonic involvement [L3, n = 80] [IgG, p = 0.6097; IgA, p = 0.3397; 
sIgA, p  =  0.8461]. However, there was a higher IgG reactivity to 
CHI3L1 in L3 compared to L2 patients [p  =  0.0250] but only a 
trend for higher IgA and sIgA [p = 0.0856 and 0.0586, respectively] 
[Figure 4, Table 6].
Independent on anti-CHI3L1 Ig type, we found a higher preva-
lence in patients with both ileal and ileolcolonic involvement, but 
the trends did not reach significance for either anti-CHI3L1 IgG, 
anti-CHI3L1 IgA or sIgA. Nevertheless, the highest prevalence of 
anti-CHI3L1 IgG and sIgA was found in L3 patients [11.3% and 
46.3%, respectively], whereas L1 patients displayed the highest 
prevalence of anti-CHI3L1 IgA [29.4%] [Table 7, Supplementary 
Table 1].
3.6. Association of CHI3L1 autoAbs with disease 
behaviour in CD patients
We found a trend of lower IgG reactivity to CHI3L1 in patients 
with the most severe manifestation [B2+B3, stricturing and penetrat-
ing; n = 13] when compared to B2 patients [stricturing; n = 36] but 
the trend did not reach significance [p = 0.3687] [Figure 5A, Table 
6]. There was a trend of higher IgA and sIgA reactivity to CHI3L1 
in patients with more severe disease manifestation, but here as well 
the trends did not reach significance [Figure 5B and C, Table 6, 
Supplementary Table 1].
In accordance, the prevalence of CHI3L1 autoAbs was not signif-
icantly different, but there was a trend of higher prevalence of anti-
CHI3L1 IgA and sIgA [38.5% and 53.8%, respectively] in B2+B3 
patients compared with the low number of cases in B3 patients 
[Table 7, Supplementary Table 1].
Table 4. Cutoffs and performance for antibodies against CHI3L1 according to ROC curves for different clinical scenarios
 IgG IgA sIgA
Identification of CD [CD vs HC]
Area under the ROC curve [AUC] 0.597 0.711 0.781
Standard error 0.0405 0.0369 0.0324
95% confidence interval 0.525–0.666 0.642–0.773 0.717–0.837
Cut-off at 95% specificity >0.8626 >0.8123 >0.9567
Corresponding sensitivity at 95% specificity 18.18 35.45 42.73
95% Confidence interval 88.5–98.7 88.5–98.7 88.5–98.7
positive LR 3.91 7.62 9.19
negative LR 0.86 0.68 0.6
PPV 28.1 72,3 86.8
95% Confidence interval 12.2–52.4 49.2–87.5 71.2–94.6
NPV 92.1 81.2 69.9
95% Confidence interval 91.3–92.8 78.9–83.3 66.2–73.3
Differentiation between CD and UC    
Area under the ROC curve [AUC] 0.694 0.712 0.69
Standard error 0.0366 0.0362 0.0367
95% Confidence interval 0.626–0.756 0.645–0.773 0.622–0.753
Cut-off at 95% specificity >0.7404 >1.1036 >1.3315
Corresponding sensitivity at 95% specificity 29.09 23.64 20.91
95% Confidence interval 88.1–98.3 88.1–98.3 88.1–98.3
positive LR 5.53 4.49 3.97
negative LR 0.75 0.81 0.83
PPV 35.6 60.6 74.0
95% Confidence interval 18.3–57.7 38.1–79.4 53.0–87.8
NPV 93.0 78.4 62.5
95% Confidence interval 92.1–93.8 76.4–80.2 60.0–65.0
For the identification of patients with CD among healthy controls, 110 CD patients [positive criterion] and 86 blood donors [negative criterion] were analysed. 
For the differentiation of patients with CD and UC, 110 CD patients [positive criterion] and 95 UC patients [negative criterion] were analysed. ROC, receiver oper-
ating characteristic; IgG, IgA, sIgA, immunoglobulins G, A and secretory IgA; LR, likelihood ratio; PPV, positive preditictive value; NPV, negative predictive value.
Table 3. Prevalence of CHI3L1-reactive IgG, IgA and sIgA in patients with Crohn’s disease, ulcerative colitis, coaliac disease and healthy 
controls determined by ELISA
 Patients [n] IgG [n] p IgA [n] p sIgA [n] p
CD 110 10 [9.1%] 0.070 28 [25.5%] <0.0001 46 [41.8%] <0.0001
UC 95 0 0.224 9 [9.5%] 0.061 17 [17.9%] 0.006
CeD 126 3 [2.4%] 1 12 [9.5%] 0.094 11 [8.7%] 0.309
HC 86 2 [2.3%]  2 [2.3%]  4 [4.7%]  
p-values were determined by two-tailed Fisher’s exact test and describe differences in the prevalence of CHI3L1 autoAbs of disease groups compared to healthy 
controls. CHI3L1, chitinase-3-like protein 1; IgG, IgA and sIgA, immunoglobulin G, A and secretory component of IgA, respectively; ELISA, enzyme-linked immu-
nosorbent assay; CD, Crohn’s disease; UC, ulcerative colitis; CeD, coeliac disease; HC, healthy control.
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4. Discussion
Numerous efforts have been made to investigate the role of CHI3L1 
as a possible biomarker for various diseases, including IBD.24 
However, research has focused mainly on the assessment of CHI3L1 
as an analyte in patient material. This study demonstrates, for the 
first time, that CHI3L1 is an autoantigenic target in IBD as patients 
with CD demonstrate significantly elevated levels of CHI3L1 auto-
Abs compared to patients with UC or CeD or healthy controls.
In contrast to other 18-glycosylhydrolase family members, CHI3L1, 
also referred to as HC gp-39 or YKL-40, lacks chitinase activity due to 
an amino acid change in the catalytic region.25,26 Nevertheless, CHI3L1 
binds to chitooligosaccharides with high affinity. It was suggested that 
Table 5. Prevalence of CHI3L1-reactive IgG, IgA and sIgA in ASCA-positive and negative study patients
  aCHI3L1 IgG aCHI3L1 IgA aCHI3L1 sIgA
 n n [%] p n [%] p n [%] p
CD 10 28 46
ASCA+ 50 7 [14.0] 0.1823 13 [26.0] 0.8279 23 [46] 0.4377
ASCA− 58 3 [5.2]  14 [24.1]  22 [37.9]  
ND 2 0  1 [2.1]  1 [2.1]  
UC  0  9  17  
ASCA+ 5 0 1 1 [20.0] 0.3827 1 [20.0] 1
ASCA− 84 0  7 [8.3]  15 [17.9]  
ND 6 0  1 [16.7]  1 [16.7]  
CeD  3  12  11  
ASCA+ 7 0 1 4 [57.1] 0.0015 4 [57.1] 0.001
ASCA− 119 3 [2.5]  8 [6.7]  7 [5.9]  
p-values were determined by two-tailed Fisher’s exact test and describe differences in the prevalence of CHI3L1 autoAbs of ASCA-positive patient groups and 
ASCA-negative patients of the same group. ASCA, anti-Saccharomyces cerevisiae antibody; aCHI3L1 IgG/IgA/sIgA, immunoglobulin G, A and secretory compo-
















































Figure 4. Anti-CHI3L1 IgG, IgA and sIgA in patients with Crohn’s disease according to disease localization. The median ratio of ODsample/ODcutoff of anti-CHI3L1 IgG 
[A], anti-CHI3L1 IgA [B] and anti-CHI3L1 sIgA [C]. There is a trend of higher reactivity of all immunoglobulins to CHI3L1 in patients with ileal [L1] and ileocolonic 
[L3] involvement in comparison to patients with solely colonic [L2] involvement. Disease localization is described according to the Paris classification and is 
















































Figure 5. Anti-CHI3L1 IgG, IgA and sIgA according to the behaviour of Crohn’s disease. The median ratio of ODsample/ODcutoff of anti-CHI3L1 IgG [A] showed no 
significant differences when analysed according to disease behaviour, but showed a trend of lower reactivity in the most severe manifestation [B2+B3]. There 
was a trend of higher anti-CHI3L1 IgA [B] and anti-CHI3L1 sIgA [C] reactivity in the more severe manifestations of Crohn’s disease [B2, B3 and B2+B3] when 
compared to mild manifestation [B1]. OD, optical density; B1, non-stricturing and non-penetrating manifestation; B2, stricturing manifestation [stenosis]; B3, 
penetrating manifestation; B2+B3, stricturing and penetrating manifestation.
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CHI3L1 may play a role in the innate immune system by responding 
to chitinous pathogens such as fungi and nematodes.27 Besides being 
expressed in synovial cells, chondrocytes28,29 and smooth muscle cells,30 
CHI3L1 can be found in macrophages, neutrophils25,31 and colonic 
epithelial cells.32 Thus, the latter sites of expression may support an 
immune function of CHI3L1 in the intestine.
The group of Mizoguchi demonstrated an up-regulated ex-
pression of CHI3L1 in lamina propria and colonic epithelial cells 
[CECs] of UC and CD patients as well as in a murine colitis model.32 
This upregulation enhances adhesion and invasion of Salmonella 
Typhimurium and adherent-invasive E. coli [AIEC] but not of non-
pathogenic E.  coli [DH5α] in CECs. Thus, CHI3L1 may act as a 
pathogenic mediator in acute colitis. In addition, it was shown that 
CHI3L1 could bind to chitin binding protein 21 [CBP21], which is 
expressed by Serratia marcescens.33 In potentially pathogenic E. coli, 
a corresponding CBP21 homologue, ChiA, could be identified. ChiA 
has a unique amino acid motif in its chitin-binding domain, through 
which N-glycosylated CHI3L1 promotes the adhesion of AIECs to 
CECs.32–34 This possibly CHI3L1-mediated, enhanced bacterial ad-
hesion and infiltration of CECs could, in turn, be responsible for 
abscess development seen in patients with CD. These findings would 
be in accordance with our observation concerning the prevalence of 
CHI3L1 autoAbs in the more severe cases of CD. With respect to 
the low overall number of B2, B2+B3 and especially of B3 patients, 
we found a trend of higher CHI3L1 IgA reactivity in these patients. 
Later, it was shown that the carbohydrate [chitin] binding motif 
[CBM] of CHI3L1, which is essential for the interaction with chitin-
containing structures, activates protein kinase B [Akt] signalling. Akt 
signalling thus increases the secretion of pro-inflammatory cytokines 
tumour necrosis factor α [TNF-α] and interleukin 8 [IL-8] in the 
CECs,35 which trigger neutrophil recruitment, accumulation and ac-
tivation.36–38 Additionally, TNF-α and IL-8 can also be induced by 
AIECs and mucosa‐associated E. coli, respectively.39
In neutrophils, CHI3L1 is stored in specific granules and upon 
neutrophil recruitment and activation, CHI3L1 is co-mobilized with 
lactoferrin, a known antigenic target of atypical ANCA, frequently 
found in IBD patients. Of note, the tolerance break against CHI3L1 
is more pronounced at the mucosal level with a higher frequency of 
sIgA reactivity to CHI3L1 in contrast to IgG. This might explain 
the difference to ANCA, which is an IgG reactivity to neutrophil 
targets and in general reported to be characteristic for patients with 
UC. Thus, CHI3L1 is probably not the main autoantigenic target of 
ANCA occurring in such patients.
During the acute phase of inflammation, neutrophils migrate to 
the site of inflammation and serve as a first line of immune response. 
A defective neutrophil regulation in IBD is thought to play an impor-
tant role in the onset or manifestation of IBD, because it could lead 
to damage of the intestinal mucosal barrier by infiltration of neu-
trophils in the inflamed mucosa and the accumulation of pathogens 
(e.g. bacteria), which are not phagocytosed by neutrophils.18,19
Like neutrophils in the context of innate immune responses, 
IgA as an acquired immune response is involved in the defence of 
Table 7. Prevalence of CHI3L1-reactive IgG, IgA and sIgA in patients with Crohn’s disease according to disease localization and behaviour 
determined by ELISA
 Patients [n] IgG [n] IgA [n] sIgA [n]
Ileal [L1] 17 1 [5.9%] 5 [29.4%] 6 [35.3%]
Colonic [L2] 13 0 2 [15.4%] 3 [23.1%]
Ileocolonic [L3] 80 9 [11.3%] 21 [26.3%] 37 [46.3%]
Non-stricturing, non-penetrating [B1] 59 5 [8.5%] 13 [22.0%] 21 [35.6%]
Stricturing [B2] 36 4 [11.1%] 9 [25.0%] 17 [47.2%]
Penetrating [B3] 2 0 1 [50%] 1 [50.0%]
Stricturing and penetrating [B2+B3] 13 1 [7.7%] 5 [38.5%] 7 [53.8%]
Differences of the prevalence of CHI3L1 autoAbs were not significant [p-values 0.1655–1]. IgG, IgA and sIgA, immunoglobulin G, A and secretory component 
of IgA, respectively; ELISA, enzyme-linked immunosorbent assay. L1, ileal involvement; L2, colonic involvement; L3, ileocolonic involvement; B1, non-stricturing 
and non-penetrating manifestation; B2, structuring manifestation [stenosis]; B3, penetrating manifestation; B2+B3, stricturing and penetrating manifestation.
Table 6. Median ratio of ODsample/ODcutoff and 95% confidence interval of IgG, IgA and sIgA reactivity to CHI3L1 of Crohn’s disease sera ac-
cording to disease localization and behaviour as determined by ELISA and Mann–Whitney U test
 IgG IgA sIgA
 OD 95% CI OD 95% CI OD 95% CI
L1 0.57 0.43–0.69 0.73 0.41–1.28 0.81 0.57–1.28
L2 0.47 0.25–0.58 0.424 0.26–0.68 0.54 0.34–1.07
L3 0.54 0.52–0.69 0.68 0.54–0.81 0.90 0.69–1.08
B1 0.53 0.51–0.63 0.58 0.41–0.68 0.62 0.51–0.99
B2 0.56 0.44–0.69 0.72 0.54–0.89 0.85 0.69–1.21
B3 0.59 0.38–0.81 0.90 0.49–1.31 0.86 0.52–1.20
B2+B3 0.46 0.42–0.78 0.83 0.62–1.49 1.01 0.76–1.68
OD, optical density; CI, confidence interval; IgG, IgA and sIgA, immunoglobulin G, A and secretory component of IgA, respectively; ELISA, enzyme-linked 
immunosorbent assay; L1, ileal involvement; L2, colonic involvement; L3, ileocolonic involvement; B1, non-stricturing and non-penetrating manifestation; B2, 
stricturing manifestation [stenosis]; B3, penetrating manifestation; B2+B3, stricturing and penetrating manifestation.
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the intestinal epithelium. Both may protect the intestinal epithe-
lium from enteric toxins and pathogenic microorganisms in a non-
inflammatory manner. In brief, IgA dimers secreted by intestinal B 
cells can be actively translocated to the epithelial cell surface as sIgA. 
Consequently, sIgA could interact with dietary antigens and micro-
organisms, reduce pro-inflammatory bacterial epitope expression, 
modulate attachment of microbes to epithelial cells and induce intra-
epithelial neutralization of inflammatory products or pathogens.40,41 
Interestingly, IgA immune complexes trigger the IgA Fc receptor 
[FcαRI] on neutrophils, and thus it may initiate pro-inflammatory 
cellular processes.42 Although this may explain the tolerance breach 
to CHI3L1 and the occurrence of IgA autoAbs to this particular 
target, the exact role and underlying mechanisms of CHI3L1 in the 
pathogenesis of IBD remain unclear.
Interestingly, the role of CHI3L1 in inflammatory conditions was 
first described in patients with rheumatoid arthritis, where elevated 
serum CHI3L1 levels were reported in active disease and addition-
ally correlated with two other pro-inflammatory markers, IL-6 and 
CRP. In addition, an increased tissue expression was found in chon-
drocytes of arthritic cartilage as well as in lining and stromal cells 
[macrophages] in the synovium. Until now, rheumatoid arthritis 
was the only chronic inflammatory condition reportedly displaying 
autoantibodies to CHI3L1.43–46
Furthermore, CHI3L1 autoAbs may also be involved in the 
development of strictures and fistulas in patients with CD, as 
increased serum CHI3L1 was associated with stricture formation.47 
This might be underlined by the fact that CHI3L1 was reported to 
play a role in tissue remodelling and cell migration and adhesion 
in different cell types. In fact, CHI3L1 was shown to act as a mito-
gen or growth factor in, for example, chondrocytes and synovial 
cells, stimulating tissue remodelling by interaction with insulin-like 
growth factor 1 [IGF-1]. Additionally, it acts as a chemoattractant in 
vascular endothelial cells [HUVECs], stimulating cell migration and 
adhesion.30,48–51
In general, our observation is in accordance with other work, 
demonstrating that serum CHI3L1 levels correlate with disease ac-
tivity in IBD patients.52 About half of CD patients show increased 
serum CHI3L1, and these levels do not decrease when the disease 
becomes inactive. In contrast, although half of UC patients also 
display higher CHI3L1, these levels drop when the disease be-
comes inactive and correlate with the simple clinical colitis activity 
index [SCCAI].52,53 A persistently high CHI3L1 level could increase 
the risk for a tolerance break in CD, resulting in the formation of 
autoAbs to CHI3L1 in these patients. In contrast, this tolerance 
break might not be seen in UC, due to disease activity-dependent 
variations in CHI3L1 levels. However, the difference of stable 
and varying CHI3L1 serum levels in IBD could explain the higher 
prevalence of IgA and sIgA CHI3L1 autoAbs in patients with CD 
compared to UC patients. In this context, IgA and/or sIgA CHI3L1 
autoAbs could be a new marker for the differentiation of IBD.
Serum CHI3L1 may not be suitable for the differentiation of CD 
and UC and monitoring disease activity, but like CRP, faecal calpro-
tectin and faecal lactoferrin, faecal CHI3L1 could be used to ob-
serve disease activity.54–56 Faecal CHI3L1 appears to correlate with 
endoscopic activity in CD patients.57,58 Although this work showed 
a higher prevalence of anti-CHI3L1 IgA and sIgA in CRP-positive 
compared to CRP-negative CD patients, there was no significant 
correlation of the CRP level with the autoAb reactivity to CHI3L1. 
Similar results were found for UC patients, in whom CRP levels also 
did not correlate with CH3L1 reactivity.
The most extensively studied serological markers for differen-
tiation are ANCA,7,59 ASCA,14,60 goblet cell antibodies [GAB]9,10 and 
pancreatic antibodies [PAB],11 which are utilized in different combi-
nations for the differentiation of IBD. Regarding the combinations 
ANCA+/ASCA− and ANCA−/ASCA+, a specificity of 81–98% for 
UC and 92–97% for CD achieved.59 Patients are also more likely 
to have CD when they were tested positive for ASCA and PAB and 
negative for ANCA and GAB.14 In conclusion, integrating IgA and/or 
sIgA antibodies against CHI3L1 along with other novel CD-specific 
autoAbs such as antibodies to the zymogen granule GP2 into the lab-
oratory screening of patients with a suspicion of CD might increase 
the serological sensitivity and the specificity of the screening.
Future work should examine whether there is diagnostic poten-
tial with CHI3L1 autoAbs and whether increased CHI3L1 levels and 
anti-CHI3L1 antibodies are an epiphenomenon particularly in CD 
or contribute to the onset or progress of IBD.
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